News You Can Use
Updates and news related to prostate cancer:
Talzenna Plus Xtandi May Improve Survival in Metastatic Castration-Resistant Prostate Cancer
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.
Hydroablation Device Shows Promise for Early Prostate Cancer
Clearance of all visible prostate lesions at 6 months in five treated patients.
Highlights of the 31st Annual PCF Scientific Retreat
Advancing prostate cancer science through clinical trials and powerful data
Testosterone Therapy and Prostate Cancer
Risk-benefit and individualized treatment
PSA Bounce
Understanding temporal fluctuations in prostate cancer after external radiotherapy
Testosterone Supplementation After Treatment for Localized Prostate Cancer
Early data has not demonstrated any increased risk of prostate cancer recurrence or progression in men using testosterone replacement therapy after prostate cancer.
The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer
It is important to consider disease volume, whether presentation with mCSPC is de novo, presence of comorbid conditions, and eligibility for docetaxel chemotherapy treatment.
Contemporary Prostate Cancer Radiation Therapy Trials
Do they underestimate the risk of biochemical recurrence?
PSMA-PET Shows Diagnostic Accuracy in Initial Staging of Prostate Cancer
Findings from a recent study show that PSMA-PET may have diagnostic value in the initial staging of patients with intermediate- and high-risk prostate cancer.
Prolaris’ Value in Predicting Prostate Cancer Outcomes
The National Comprehensive Cancer Network (NCCN) has endorsed the Prolaris prostate cancer prognostic test, reinforcing its position as a critical tool in prostate cancer prognostication.